154 related articles for article (PubMed ID: 20147398)
1. Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry.
Alexander M; Lynch R; Mulenga J; Allen S; Derdeyn CA; Hunter E
J Virol; 2010 Apr; 84(8):4100-4. PubMed ID: 20147398
[TBL] [Abstract][Full Text] [Related]
2. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization.
Isaacman-Beck J; Hermann EA; Yi Y; Ratcliffe SJ; Mulenga J; Allen S; Hunter E; Derdeyn CA; Collman RG
J Virol; 2009 Aug; 83(16):8208-20. PubMed ID: 19515785
[TBL] [Abstract][Full Text] [Related]
3. Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.
Chikere K; Webb NE; Chou T; Borm K; Sterjovski J; Gorry PR; Lee B
Retrovirology; 2014 Jun; 11():48. PubMed ID: 24957778
[TBL] [Abstract][Full Text] [Related]
4. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.
Parker ZF; Iyer SS; Wilen CB; Parrish NF; Chikere KC; Lee FH; Didigu CA; Berro R; Klasse PJ; Lee B; Moore JP; Shaw GM; Hahn BH; Doms RW
J Virol; 2013 Mar; 87(5):2401-11. PubMed ID: 23269796
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 clade C envelopes obtained from late stage symptomatic Indian patients varied in their ability towards relative CD4 usages and sensitivity to CCR5 antagonist TAK-779.
Gharu L; Ringe R; Bhattacharya J
Virus Res; 2011 Jun; 158(1-2):216-24. PubMed ID: 21524671
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 non-macrophage-tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4+ T-cells than envelopes highly adapted for macrophages.
Musich T; O'Connell O; Gonzalez-Perez MP; Derdeyn CA; Peters PJ; Clapham PR
Retrovirology; 2015 Mar; 12():25. PubMed ID: 25809903
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal analysis of subtype C envelope tropism for memory CD4
Gartner MJ; Gorry PR; Tumpach C; Zhou J; Dantanarayana A; Chang JJ; Angelovich TA; Ellenberg P; Laumaea AE; Nonyane M; Moore PL; Lewin SR; Churchill MJ; Flynn JK; Roche M
Retrovirology; 2020 Aug; 17(1):24. PubMed ID: 32762760
[TBL] [Abstract][Full Text] [Related]
8. Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry.
Loftin LM; Kienzle MF; Yi Y; Lee B; Lee FH; Gray L; Gorry PR; Collman RG
Virology; 2010 Jun; 402(1):135-48. PubMed ID: 20381825
[TBL] [Abstract][Full Text] [Related]
9. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.
Hu Q; Huang X; Shattock RJ
J Gen Virol; 2010 Dec; 91(Pt 12):2965-73. PubMed ID: 20810746
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
11. Quantifying CD4/CCR5 Usage Efficiency of HIV-1 Env Using the Affinofile System.
Webb NE; Lee B
Methods Mol Biol; 2016; 1354():3-20. PubMed ID: 26714701
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.
Pena-Cruz V; Etemad B; Chatziandreou N; Nyein PH; Stock S; Reynolds SJ; Laeyendecker O; Gray RH; Serwadda D; Lee SJ; Quinn TC; Sagar M
Retrovirology; 2013 Dec; 10():162. PubMed ID: 24369910
[TBL] [Abstract][Full Text] [Related]
13. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
14. Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virus.
King DF; Siddiqui AA; Buffa V; Fischetti L; Gao Y; Stieh D; McKay PF; Rogers P; Ochsenbauer C; Kappes JC; Arts EJ; Shattock RJ
J Virol; 2013 Jan; 87(2):890-9. PubMed ID: 23135721
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.
Wilen CB; Parrish NF; Pfaff JM; Decker JM; Henning EA; Haim H; Petersen JE; Wojcechowskyj JA; Sodroski J; Haynes BF; Montefiori DC; Tilton JC; Shaw GM; Hahn BH; Doms RW
J Virol; 2011 Sep; 85(17):8514-27. PubMed ID: 21715507
[TBL] [Abstract][Full Text] [Related]
16. Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype.
Nedellec R; Coetzer M; Shimizu N; Hoshino H; Polonis VR; Morris L; Mårtensson UE; Binley J; Overbaugh J; Mosier DE
J Virol; 2009 Sep; 83(17):8353-63. PubMed ID: 19553323
[TBL] [Abstract][Full Text] [Related]
17. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
Tilton JC; Amrine-Madsen H; Miamidian JL; Kitrinos KM; Pfaff J; Demarest JF; Ray N; Jeffrey JL; Labranche CC; Doms RW
AIDS Res Hum Retroviruses; 2010 Jan; 26(1):13-24. PubMed ID: 20055594
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.
Gray L; Roche M; Churchill MJ; Sterjovski J; Ellett A; Poumbourios P; Sherieff S; Wang B; Saksena N; Purcell DF; Wesselingh S; Cunningham AL; Brew BJ; Gabuzda D; Gorry PR
J Virol; 2009 Jun; 83(11):5430-41. PubMed ID: 19321618
[TBL] [Abstract][Full Text] [Related]
19. Adhesion and fusion efficiencies of human immunodeficiency virus type 1 (HIV-1) surface proteins.
Dobrowsky TM; Rabi SA; Nedellec R; Daniels BR; Mullins JI; Mosier DE; Siliciano RF; Wirtz D
Sci Rep; 2013 Oct; 3():3014. PubMed ID: 24145278
[TBL] [Abstract][Full Text] [Related]
20. Variable infectivity and conserved engagement in cell-to-cell viral transfer by HIV-1 Env from Clade B transmitted founder clones.
Li H; Chen BK
Virology; 2019 Jan; 526():189-202. PubMed ID: 30415130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
